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A B S T R A C T
Epigallocatechin-3-gallate (EGCG) is a candidate for treatment of Alzheimer's disease (AD) but its inherent instability
limits bioavailability and effectiveness. We found that EGCG displayed increased stability when formulated as dual-
drug loaded PEGylated PLGA nanoparticles (EGCG/AA NPs). Oral administration of EGCG/AA NPs in mice resulted
in EGCG accumulation in all major organs, including the brain. Pharmacokinetic comparison of plasma and brain
accumulation following oral administration of free or EGCG/AA NPs showed that, whilst in both cases initial EGCG
concentrations were similar, long-term (5–25 h) concentrations were ca. 5 fold higher with EGCG/AA NPs. No
evidence was found that EGCG/AA NPs utilised a specific pathway across the blood-brain barrier (BBB). However,
EGCG, empty NPs and EGCG/AA NPs all induced tight junction disruption and opened the BBB in vitro and ex vivo.
Oral treatment of APPswe/PS1dE9 (APP/PS1) mice, a familial model of AD, with EGCG/AA NPs resulted in a marked
increase in synapses, as judged by synaptophysin (SYP) expression, and reduction of neuroinflammation as well as
amyloid β (Aβ) plaque burden and cortical levels of soluble and insoluble Aβ(1-42) peptide. These morphological
changes were accompanied by significantly enhanced spatial learning and memory. Mechanistically, we propose that
stabilisation of EGCG in NPs complexes and a destabilized BBB led to higher therapeutic EGCG concentrations in the
brain. Thus EGCG/AA NPs have the potential to be developed as a safe and strategy for the treatment of AD.
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AD is the most common form of dementia worldwide [1] and in-
volves 60–80% of all reported dementias. It is characterized by cogni-
tive decline and, ultimately, by an incapacitation of basic functions,
such as swallowing or walking that leads to death [2]. In 2005, the
Delphi Consensus Study predicted that, by the year 2020, 42.3 million
people in the world will have developed dementia, and that by 2040
this number will have doubled [3]. This increase in dementia cases will
be accompanied by a large economic burden, which currently stands at
around a trillion dollar worldwide [4].
The incidence of AD increases with age, but its exact etiology re-
mains unknown. The main hypothesis of pathogenesis focuses on the
alteration in the amyloidogenic pathway and Tau hyperpho-
sphorylation. This is based on observations of increased accumulation
of Aβ plaques and induction of formation of neurofibrillary tangles in
the brain, respectively, both of which can lead to neuronal death and
subsequent dementia [5]. In the last decade, it has been described that
alterations in both pathways are closely related to the onset of the
disease, but also that other physiological alterations such the dereg-
ulation of cholesterol homeostasis, insulin signaling, neuroin-
flammatory processes, mitochondrial alterations or oxidative stress
contribute to the pathogenesis of this multifactorial disorder [6,7].
Due to its unknown etiology and the late appearance of the first
symptoms (which are detected when neurodegeneration is already es-
tablished), early diagnosis and effective treatment are very challenging
[8,9]. Currently, the only drugs approved for AD treatment are the
acetylcholinesterase inhibitors donepezil, galantamine and rivas-
tigmine, and the NMDA receptor antagonist memantine, for mild to
moderate and moderate to severe stages, respectively [1,5]. However,
since none of these drugs stop the progression of the disease, novel
therapeutic approaches for the treatment of AD are urgently needed
[5].
A number of new pharmacological strategies for AD have been de-
scribed [10–12]. One of them focuses on EGCG, the most abundant
polyphenol of green tea plant Camellia sinensis [13]. This catechin has a
strong chelating and antioxidant activity, due to two gallocatechol rings
which can directly remove free radicals with high efficacy [14].
EGCG has demonstrated therapeutic effectiveness in several dis-
eases, such as Down's syndrome, cancer and a variety of neurological
disorders [15–17] and is considered a safe molecule [18]. Some cases of
liver damage with EGCG consumptions higher than 800mg/day have
been reported, but in most cases these are attributed to idiosyncratic
reactions [18].
With regard to AD, pre-clinical and clinical trials have shown that
EGCG can act at different steps, such inhibiting TAU aggregation, re-
ducing Aβ accumulation, suppressing tumor necrosis factor α (TNFα),
inducible nitric oxide synthase (iNOS) or interleukin 6 (IL-6) expres-
sion, or even protecting mitochondrial function [19–22]. However,
EGCG possesses many pharmacochemical disadvantages, in particular
high instability, resulting in low EGCG bioavailability and, conse-
quently, its effectiveness [23,24]. EGCG degradation is primarily
caused by oxidation of the polyphenolic structure. Thus, potent anti-
oxidant molecules, such ascorbic acid (AA), are frequently added to
reverse this effect. In addition to scavenging oxygen and protecting
double bonds, AA also adds anti-inflammatory properties to resulting
formulations [25,26].
Another strategy to reduce degradation of drugs is their in-
corporation into nanostructured systems. In recent years, the use of
nanotechnology as a therapeutic strategy for targeting and drug de-
livery has been widely explored for diseases such as cancer, diabetes or
neurodegenerative disorders [27–29].
Among several types of nanocarriers, polymeric NPs have been
widely exploited for drug delivery and targeting, due to their versatility
and production facilities. These nanosystems display a high loading
capacity of a range of chemically different drugs. In addition, they offer
the possibility of attaching molecules to their surface for targeting,
therefore representing an optimal alternative for the administration of
drugs [30,31]. Due to its biocompatibility, biodegradability and non-
toxicity, poly (lactic-co-glycolic acid) (PLGA) is one of the most com-
monly used polymers for the preparation of NPs [32]. Additionally,
surface PEGylation of polymeric NPs is often used to enhance in vivo
half-life. Surface tailoring NPs with polyethylene glycol (PEG) chains
reduces aggregation, improves aqueous solubility and minimizes op-
sonisation, resulting in demonstrably lower immunogenicity and en-
hanced long term stability of the nanosystem [33,34].
We hypothesized that loading of EGCG in PEGylated PLGA NPs will
improve physicochemical stability of the molecule and, consequently,
its bioavailability and therapeutic efficacy. Thus, the aims of this work
were to develop and characterize PEGylated PLGA NPs of EGCG under
an AA antioxidant environment and to evaluate their effectiveness in a
APP/PS1 double transgenic mouse model.
2. Materials and methods
2.1. Preparation of EGCG/AA NPs
EGCG/AA NPs were prepared by the double emulsion method [35]
in three steps (Supplementary Fig. S1). (i) EGCG (Capotchem Hang-
zhou, P.R.China) and AA (Sigma Aldrich, Madrid, Spain) were dissolved
in 1ml of an aqueous phase (W1) at pH 3.5 and emulsified with 1.5ml
of an oil phase (O) composed of ethyl acetate containing the dissolved
polymeric matrix (PLGA with a 5% of PEG content) (Evonik Co., Bir-
mingham, USA). A simple emulsion (W1/O) was prepared by ultra-
sound using an ultrasounds probe (Sonics&Materials, INC. Newtown,
USA) at 37% amplitude during 30 s. (ii) 2 ml of Tween®80 2.5%
(pH 4.5) (W2) (Sigma Aldrich, Madrid, Spain) was added to W1/O and
the mixture again subjected to ultrasound (37% amplitude) for 3min,
to yield a double emulsion (W1/O/W2). The entire procedure was car-
ried out on ice. (iii) 2 ml of Tween®80 0.04% was added dropwise to
stabilize the emulsion. Finally, the organic solvent was evaporated by
stirring for 24 h, resulting in a final volume of 5ml.
2.2. Optimization
Final formulation of EGCG/AA NPs with optimal physicochemical
characteristics was found using a 23 central composite factorial design
allowing optimisation with a minimum number of experiments pro-
viding maximum information. A total of 16 experiments were run as
described above in triplicate, with varying concentrations of EGCG, AA
and polymer (independent variables). The surfactant concentration was
left fixed, intended for chronic administration, in order to increase at
maximum nanocarrier stability and enhance tissue penetration [36].
The dependent variables included average particle size (Zav), poly-
dispersity index (PDI), zeta potential (ZP) and entrapment efficiency
(EE). The predicted response Y can be obtained from the non-liner
quadratic model equation as follows Eq. (1),
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where Y is the measured response, β0 the intercept, β1 to β3 the linear
coefficients, β11, β22 and β33 the square coefficients, β12, β23 and β23 the
interaction coefficients and X1, X2 and X3 are the independent studied
factors. Statgraphics Plus (16.1.18) was used to compute these models
and the effect of the factors was statically evaluated by analysis of
variance (ANOVA).
2.3. In vitro drug release
The release profile of EGCG from the polymeric matrix was de-
termined by bulk-equilibrium direct dialysis as described by Fangueiro
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et al., with some modifications [37]. Briefly, 10ml of EGCG/AA NPs
were placed in a dialysis bag (Medicell International Ltd. MWCO
12–14,000) and dialysed against 140ml of release medium, composed
of EtOH (25%, v/v), Transcutol®P (5%, v/v) and AA (0.25% w/v), pH 3
(to ensure compound stability and mimic the acid environment of the
stomach). 1 ml samples were withdrawn at regular time intervals
during 24 h from the release medium and EGCG content analysed by
HPLC as described elsewhere [38]. Total volume of release medium was
kept constant by replacement with fresh buffer throughout the experi-
ment.
2.4. Stability study
Stability of drug and NPs was carried out for: 1) the formulation of
EGCG-AA NPs; 2) EGCG in water; 3) EGCG in an aqueous solution of AA
0.25%; and 4) EGCG within the NPs formulation at storage tempera-
tures of 4 and 25 °C.
The stability study of NPs was performed with the optical analyser
Turbiscan®Lab (Formulation, L'Union, France) as described elsewhere
[39]. Samples were scanned every hour for a period of 24 h. This pro-
cess was repeated every month. Zav, PDI and ZP of were also measured
monthly.
Drug content of the NPs over time was measured at predefined
times. 300 μl of acetonitrile was added to 50 μl of EGCG/AA NPs to
break the polymer structure. Then, the total amount of EGCG was de-
termined by HPLC [38]. EGCG in water and AA 0.25% solution was also
assessed by direct HPLC measurement. EGCG concentrations were de-
rived by extrapolation to a standard curve of EGCG at 25–500 μg/ml.
2.5. Interaction studies
EGCG/AA NPs were ultracentrifuged (Optima® LE-BOK
Ultracentrifuge, Beckman, USA) at 25,000 g, 15 °C, for 15min.
Resulting pellets were dried and pulverized.
2.6. FTIR
In order to evaluate potentially new bonds generated in the manu-
facturing process of EGCG/AA NPs a Fourier transform infrared (FTIR)
study of different components was carried out. For this, a Nicolet iZ10
with an ATR diamond and DTGS detector (Thermo Scientific) was used.
3mg of powdered sample was added to 100mg of KBr and scanned at
500–4000 cm−1 in an inert nitrogen/argon atmosphere.
2.7. Differential scanning calorimetry
Differential scanning calorimetry (DSC) was carried out as pre-
viously described [40]. Briefly, samples were weighed (1–3mg) in a
perforated aluminium pan and analysed in a TA 4000 system (Mettler,
Greifensee, Switzerland) equipped with a DSC 25 cell. Heating was
performed under a nitrogen atmosphere and a flow rate of 10 °C/min
(40–280 °C). Thermograms were analysed with STARe V 9.01 dB soft-
ware (Mettler, Greifensee, Switzerland).
2.8. Nanoparticles transport across the BBB in vitro
Primary brain microvascular endothelial cells (BMVECs) were iso-
lated from rat cortical grey matter microvessels as described elsewhere
[41] and seeded onto collagen IV/fibronectin coated Transwells®
(12mm, Costar 3401, Sigma Aldrich, UK) at high density (6 rat brains
per 50 cm2). BMVECs were cultured in EBM®-2 MV (Lonza, UK) sup-
plemented with 5 μg/ml puromycin during the initial 3 days, until
transendothelial electric resistance (TEER) was above 200Ω/cm2 (after
2–3 weeks).
In order to measure transport across this in vitro BBB, EGCG/AA
NPs were covalently labelled with Rhodamine 110 (Sigma Aldrich,
Madrid, Spain) (12mg/g of labelled polymer) as previously described
[42,43] to produce EGCG/AA NPs-Rho. These were then added at in-
creasing concentrations to the apical side of primary rat BMVECs grown
on Transwell® filters. 50 μl of medium were removed from the basal
chamber (and replaced by fresh medium) at 20min intervals for 24 h.
Fluorescence was measured in a Safire microplate reader (Tecan,
Reading, UK) at 496/520 nm.
2.9. Effect of EGCG/AA NPs on the in vitro BBB
Flux of 4 kDa fluorescein (FITC dextran) (Sigma Aldrich, UK) across
primary rat BMVECs was measured as described previously [41].
Baseline flux was recorded for 2 h at which point free or encapsulated
EGCG was added to the apical chamber and flux recorded for another
2–3 h. Changes of flux were expressed as linear changes of flux before
and after addition of EGCG or NPs samples.
Alternatively, primary rat BMVECs were seeded on collagen type
IV/fibronectin gold-coated ECIS 8W10E electrode arrays (Applied
Biophysics) and real-time impedance changes and extrapolated TEER
measured in response to EGCG and NPs treatments [41].
2.10. Rat BMVECs staining
Monolayer of rat primary BMVECs grown on collagen IV/fi-
bronectin coated Transwell® filters were treated with free or en-
capsulated EGCG. After 2 h, cells were fixed with −20 °C MeOH and
then stained for Cldn-5 (1200, Thermo Fisher Scientific, UK) and nu-
clear DNA (Bisbenzimide) exactly as previously described [41]. Images
were acquired on a Zeiss Axioskop 2 (Cambridge, UK) using a Hama-
matsu camera and HCimage software (Hamamatsu Photonics, Hert-
fordshire, UK).
2.11. Effect of EGCG/AA NPs on the neurovascular unit ex vivo
Rats were asphyxiated using CO2 and immediately processed for
bilateral carotid arteries cannulation. The head was first perfused with
heparin (300 U/ml in isotonic saline) and then with cardioplegic solu-
tion (10mM MgCl2, 110mM NaCl, 8 mM KCl, 10mM HEPES, 1mM
CaCl2, 10 μM isoproterenol), known to protect blood-neural barriers
[44]. Perfusates containing Evans Blue (5 g/l in 10% BSA) in cardio-
plegic solution with or without EGCG or NPs at various concentrations
were administered simultaneously via both carotid cannulae under
equal delivery pressure (thus avoiding mixing at the Circle of Willis).
After 1 h incubation, the drug-containing perfusates were washed out
and brains were fixed with 4% PFA (w/v in PBS) for 24 h before sec-
tioning and imaging of Evans Blue accumulation in brain areas on an
Olympus SZX16 stereomicroscope.
2.12. In vivo studies
6months-old male APP/PS1 and control wild type C57BL/6 (WT)
mice were used [45]. These transgenic mice express a Swedish
(K594M/N595L) mutation of a chimeric mouse/human APP (mo/
huAPP695swe), together with the human exon-9-deleted variant of PS1
(PS1-dE9), all of which leads to high expression of Aβ peptide. Animal
groups and treatments timelines are shown in Fig. S2 of Supplementary
material. Daily EGCG treatments were provided orally in the drinking
water at a dose of 40mg/kg (free or encapsulated). All animals were
kept under controlled temperature, humidity and light conditions and
given access to food and water ad libitum. Every effort was made to
reduce the number of animals and minimize animal suffering. Mice
were treated in accordance with the European Community Council
Directive 86/609/EEC, the procedures established by the Department
d'Agricultura, Ramaderia i Pesca of the Generalitat de Catalunya and
approved by the local ethical committee (University of Barcelona).
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2.13. In vivo biodistribution of EGCG/AA NPs
WT mice were given a single dose of 40mg/kg of EGCG/AA NPs-
Rho (expressed in EGCG concentration) or a corresponding dose of free
Rhodamine (2.7mg/kg) by oral gavage. After 24 h they were divided in
two groups and sacrificed by: (i) cardiac perfusion with PFA 4% (pre-
viously anesthetized by intraperitoneal (i.p.) injection of sodium pen-
tobarbital 80mg/kg) and (ii) cervical dislocation. From the first group,
brain coronal sections of 20 μm of thickness were cut on a cryostat
(Leica Microsystems, Wetzlar, Germany) for rhodamine visualization
under an epifluorescence microscope (Olympus BX61, Barcelona,
Spain). From the second group, different organs were collected and
processed to determine the biodistribution of EGCG/AA NPs by de-
tecting the EGCG amount by LC-MS-MS as described elsewhere [46]. All
measurements were run in triplicate.
2.14. Pharmacokinetic assay
40mg/kg of EGCG/AA NPs (expressed as EGCG concentration) and
free EGCG were administered to WT mice by oral gavage. To evaluate
the pharmacokinetic profile, animals were anesthetized with isoflurane
and sacrificed by cardiac puncture at different time intervals. Blood and
brain were collected to measure EGCG amount by LC-MS-MS. Samples
processing was performed as described Chen et al. with some mod-
ifications [47]. Briefly, blood samples were centrifuged at 4.000 g
during 4min at 4 °C, plasma was removed, extracted with ethyl acetate
twice and resuspended in 20% AA, 10% acetonitrile. Brains were
weighed, homogenized in 20% AA, 0.5 mg/ml Na2EDTA, PBS 0.4M and
centrifuged at 16.000 g during 10min at 4 °C. Then, supernatant was
extracted the same as those plasma samples. All measurements were
run in triplicate.
2.15. Behavioural test
2.15.1. Morris water maze
Morris water maze (MWM) test was performed in a circular tank
with latex white water and a platform, which was kept in the same
position during all the experiment, submerged 1 cm below the water
surface. Temperature and intensity of light were kept at 25 ± 2 °C and
30 lx throughout all the days. The procedure was based on six training
days (1min per trial) and one test day. On the test day, the platform
was removed and the mouse was placed in the tank in the quadrant
opposite to where the platform used to be for 1min. The behavioural
data were acquired and analysed using SMART V3.0 (Panlab Harvard
Apparatus, Germany) video tracking system.
2.15.2. Novel object recognition
Novel object recognition (NOR) test was used as indicator of cog-
nitive impairment [48]. Briefly, in a first phase of habituation (days
1–3), mice were placed in an open field (without any object) to fa-
miliarize themselves with. On day 4, two identical objects were placed
at equidistance and the exploration time of each one was recorded. On
the day of the test the same process was repeated by changing one of
the familiar objects to a different one (novel object). The duration of
each trial was 10min. The results of the test were expressed as (eq. 2):
=Exploration time (%) Exploration time of new object (s)
Total exploration time (s)
·100 (2)
2.15.3. Immunohistochemistry and Thioflavin-S staining
At the end of treatments and behavioural studies, mice were sacri-
ficed by i.p. injection of ketamine/xylazine (100/10mg/kg, respec-
tively) and perfusion with 4% PFA. Brains were removed and main-
tained at 4 °C in 30% sucrose, 4% PFA solution until they were cut in
20 μm coronal sections using a cryostat (Leica Microsystems, Wetzlar,
Germany). Sections were stained as described elsewhere [40]. Primary
polyclonal antibodies against glial fibrillary acidic protein (GFAP)
(1:1000; Dako Chemicals, Glostrup, Denmark) and Synaptophysin
(SYN) (1200, Dako Products, Sta. Clara, CA, USA) and secondary an-
tibodies AlexaFluor 594 goat anti-rabbit (Red, 1:1000; Life Technolo-
gies, Cambridge, UK) and AlexaFluor 488 goat anti-mouse (Green,
1:1000; Life Technologies, Cambridge, UK), were used. Image acquisi-
tion was carried out with an epifluorescence microscope (BX41,
Olympus, Germany).
To detect Aβ plaques in brain slides, Thioflavin-S (ThS) staining was
performed as described elsewhere [49]. Briefly, brain sections were
incubated with 5ml of ThS 0.3% and washed twice with 10ml of EtOH
50% and PBS. Slides were mounted with Fluoromount on gelatin-coated
glass microscope and observed under the epifluorescence microscope.
Plaque quantification was carried out using the same areas, focusing on
the hippocampus and cortical area.
2.15.4. Evaluation of β-amyloid peptides levels
Measurement of Aβ(1-42) peptides in cortical tissues was carried out
using a commercially available human ELISA according to manufac-
turer's guideline kit (Cat # KHB3441; Invitrogen, Camarillo, CA, USA).
Table 1
Optimization study results of EGCG/AA NPs by 23 central composite factorial design.








Coded level (mg/ml) Coded level (mg/ml) Coded level (mg/ml)
F1 −1 2 −1 2 −1 12 126.5 ± 4.1 0.063 ± 0.019 −17.8 ± 0 0.5 94.4 ± 4.5 91.1 ± 2.1
F2 1 3 −1 2 −1 12 174.7 ± 11.4 0.060 ± 0.004 −19.9 ± 0.6 97.5 ± 3.2 90.5 ± 6.1
F3 −1 2 1 3 −1 12 121.7 ± 0.9 0.070 ± 0.001 −13.6 ± 0.8 96.1 ± 1.2 90.3 ± 2.7
F4 1 3 1 3 −1 12 185.1 ± 8.2 0.586 ± 0.085 −16.1 ± 2.1 97.8 ± 1.3 92.5 ± 1.1
F5 −1 2 −1 2 1 16 126.5 ± 6.1 0.067 ± 0.003 −14.5 ± 0.8 96.5 ± 1.3 94.2 ± 4.2
F6 1 3 −1 2 1 16 144.6 ± 27.1 0.255 ± 0.110 −20.7 ± 2.3 97.9 ± 2.8 95.1 ± 1.2
F7 −1 2 1 3 1 16 134.1 ± 5.0 0.050 ± 0.012 −14.9 ± 1.6 96.8 ± 2.4 95.8 ± 3.1
F8 1 3 1 3 1 16 176.5 ± 18.9 0.183 ± 0.098 −17.1 ± 3.5 98.0 ± 0.8 97.0 ± 1.3
Axial points
F9 −1.68 1.66 0 2.5 0 14 119.6 ± 5.9 0.076 ± 0.006 −12.6 ± 0.8 95.9 ± 4.5 93.9 ± 1.2
F10 1.68 3.34 0 2.5 0 14 512.4 ± 64.0 0.293 ± 0.126 −11.5 ± 0.8 97.2 ± 2.6 95.5 ± 2.1
F11 0 2.5 −1.68 1.66 0 14 277.4 ± 20.9 0.284 ± 0.207 −18.2 ± 0.8 96.4 ± 1.9 90.6 ± 2.4
F12 0 2.5 1.68 3.34 0 14 135.0 ± 10.1 0.062 ± 0.015 −12.5 ± 0.1 97.1 ± 1.3 95.3 ± 0.6
F13 0 2.5 0 2.5 −1.68 10.64 186.7 ± 2.3 0.169 ± 0.064 −14.1 ± 1.6 96.3 ± 2.1 90.1 ± 2.4
F14 0 2.5 0 2.5 1.68 17.36 129.7 ± 4.3 0.061 ± 0.006 −18.3 ± 0.4 95.7 ± 3.1 96.9 ± 0.7
Central points
F15 0 2.5 0 2.5 0 14 124.8 ± 5.2 0.054 ± 0.013 −15.1 ± 1.7 97.1 ± 2.4 94.3 ± 1.6
F16 0 2.5 0 2.5 0 14 129.6 ± 5.2 0.063 ± 0.013 −15.7 ± 1.7 96.5 ± 2.4 96.1 ± 1.7
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Aβ content of cortical extracts homogenates was expressed in pico-
grams of Aβ per milligrams of total protein [45].
2.15.5. Statistical analysis
Data are presented as the mean ± S.D. One-way ANOVA followed
by Tukey post hoc test was performed for groups comparison using
GraphPad 6.0 Prism. Statistical significance was set at p˂0.05 (*).
3. Results
3.1. Optimization and physicochemical characteristics of EGCG/AA NPs
Physicochemical characteristics of 16 formulations tested in the 23
composite central factorial design are shown in Table 1. From this an
optimal formulation was chosen consisting of 2.5 mg/ml of EGCG,
2.5 mg/ml of AA and 14mg/ml of PLGA-5% PEG. Tween®80 con-
centration of the aqueous phase W2 and outer covering was 2.5 and
0.04% (i.e. resulting in a final concentration of 1.016% of surfactant).
EGCG/AA NPs optimized in this way exhibited a monodiperse popu-
lation (PDI 0.054 ± 0.013) with a Zav of 124.8 ± 5.2 nm. The re-
sponse surface showed a direct relationship of EGCG concentration and
Zav and PDI; both decreasing as the amount of EGCG decreased (Fig. 1A
and B). The optimized formulation showed a ZP of ca. −15mV
(Fig. 1C). EGCG EE was higher than 97%, slightly decreasing at low
concentrations of PLGA-PEG (Fig. 1D). AA EE value was higher than
94%.
3.2. Interaction studies
No covalent bonds were observed between both drugs and polymer
in line with our previous studies [40]. EGCG FTIR profile exhibited
typical peaks at 1543, 1690 and 3356 cm−1 which correspond to CeC
stretch in aromatic ring, a C]O group that links the trihydrox-
ybenzoate and chroman groups and a OH group attached to the aro-
matic ring, respectively [50]. AA exhibited intense bands at 1322 and
1674 cm−1, which correspond to the enol hydroxyl group and the
stretching vibration of the C]C group, respectively [51]. PLGA-PEG
showed a peak at 1743 cm−1 corresponding to the CeO stretching vi-
bration of the carbonyl groups of lactic and glycolic acid. Intense bands
were also detected between 2900 and 2950 cm−1 due to the CeH
stretching of PLGA-PEG [52]. Drug-loaded NPs exhibited a very similar
FTIR profile to polymer, as well as empty NPs, but not as EGCG FTIR
pattern. The encapsulation of the drug was evident by an important
decrease of the absorbance in the EGCG/AA NPs profile against the
polymer profile (Fig. S3A of Supplementary material).
EGCG and AA exhibited similar DSC profiles due to their common
crystalline chemical structure (Fig. S3B of Supplementary material).
Endothermic peaks of melting transition at 225 and 195 °C, respec-
tively, more intense in the case of AA, were observed. These peaks were
followed by an exothermic peak at 235 °C in both cases, which is related
to the melting process of the drugs. Drug-loaded NPs and empty NPs
DSC profiles were similar to that of polymer itself, suggesting that both
molecules may converge to an amorphous or disordered crystalline
form which led to their inclusion inside the NPs [50].
These results suggest that both EGCG and AA were dissolved in the
form of a molecular dispersion and successfully included into the PLGA-
PEG matrix.
3.3. NP formulated EGCG displays improved physicochemical stability
EGCG/AA NPs were stored at either 4 °C and 25 °C for extended
periods. Backscattering profiles were established to determine stability
(Fig. 2A and B). The formulation only became instable after 4 mo of
storage at 25 °C. At this time, it was also noted that coloration of the
normally white sample turned brown, presumably due to the oxidation
of both drugs. Furthermore a precipitate appeared presumably due to
Fig. 1. Results of EGCG/AA NPs optimization study. (A) Response surface of
size at fixed value of AA 2.5mg/ml. Optimized value 124.8 ± 5.2 nm. (B)
Response surface of PDI at fixed value of AA 2.5mg/ml. Optimized value
0.054 ± 0.013. (C) Response surface of ZP at fixed value of EGCG 2.5mg/ml.
Optimized value −15.1 ± 1.7mV. (D) Response surface of EGCG EE at fixed
value of AA 2.5mg/ml. Optimized value 97.1 ± 2.4 (%).
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degradation of the polymeric matrix [53] (Fig. S4 of Supplementary
material). By contrast, ECGC/AA NPs stored at 4 °C remained stable for
up to 11months. Zav, PDI and ZP measurements confirmed these results
(Table S1 of Supplementary material).
HPLC measurements showed that free EGCG suffered fast degrada-
tion when it was dissolved in aqueous solutions. The half-life of EGCG
in water was ca. 3 and 8 days at 25 °C and 4 °C, respectively, in ac-
cordance with a previous report by Proniuk et al. [54]. The addition of
AA 0.25% increased half-life of the drug to ca. 9 and 15 days at 25 °C
and 4 °C, respectively. In contrast, EGCG incorporated in EGCG/AA NPs
maintained at least 80% of its integrity for 1 mo at both temperatures
(Fig. 2C).
3.4. In vitro drug release profile
One of the main advantages of polymeric controlled drug delivery
systems is sustained release of encapsulated drugs, which is usually
governed by a diffusion/degradation process [53]. The drug release
profile of EGCG/AA NPs was determined in vitro by dialysis against a
release medium at acid pH, taking into consideration the EGCG in-
stability at neutral pH and, in preparation of oral use of EGCG/AA in
mice (see below), the acid environment of the stomach [55–57]. When
free EGCG was dialysed, its concentration in the dialysate reached the
theoretical equilibrium concentration after about 10 h (Fig. 2D). In
contrast only 23% of EGCG had been released from EGCG/AA NPs to
the dialysate at that time. After 24 h, NPs had released almost 50% of
EGCG. Taken together this indicated that our NP formulation displayed
characteristics of sustained release.
3.5. In vivo biodistribution and EGCG pharmacokinetics
3months-old C57BL/6 mice were treated with and single oral dose
of EGCG/AA NPs 40mg/kg. After 24 h EGCG content was determined
in various organs (Fig. 3A). EGCG had accumulated strongly in the
liver. Whilst in the brain, EGCG concentration was ca. 10 times lower,
brain accumulation constituted ca. 0.025% of the administered EGCG.
Pharmacokinetic profiles of EGCG were established after an oral ad-
ministration both of EGCG/AA NPs and free EGCG (Fig. 3B and C,
Table 2). After 1 h, maximal EGCG plasma concentrations were very
similar under both conditions (1078.976 ± 242.238 ng/ml for free
EGCG v. 842.590 ± 78.911 ng/ml for EGCG/AA NPs). Thereafter,
whilst a rapid decrease in plasma EGCG concentration was observed in
mice administered with free EGCG (to 60.267 ± 40.150 ng/ml after
24 h), EGCG plasma concentration stabilised at ca. 500 ng/ml (with
361.346 ± 156.176 ng/ml at 24 h) in mice treated with EGCG/AA
NPs. Analysis of AUC of plasma EGCG concentrations revealed sig-
nificant differences with 10,270.624 ± 123.564 h.ng/ml following
oral treatment with EGCG/AA NPs and only 4509.790 ± 65.411 h.ng/
ml following free EGCG.
A similar pharmacokinetic profile was observed in the brain of these
mice. EGCG reached maximal concentration of 0.908 ± 0.162 ng/mg
when it was administered encapsulated in NPs, as compared to
0.826 ± 0.206 ng/mg following free form administration. Again cer-
ebral EGCG concentrations stabilised at a significantly higher con-
centrations following EGCG/AA NPs, with EGCG concentrations of
0.561 ± 0.119 ng/mg and 0.111 ± 0.022 ng/mg at 24 h, following
treatment with EGCG/AA NPs and free EGCG, respectively. AUC ana-
lyses showed 14.410 ± 3.511 and 6.426 ± 0.811 h.ng/mg following
encapsulated and free administration, respectively. Overall these data
indicated that NPs stabilised circulating EGCG and consequently cere-
bral accumulation of the drug.
EGCG brain penetration was investigated indirectly by histochem-
ical analysis in mice following a single oral dose of EGCG/AA NPs-Rho.
Inspection of fixed coronal sections revealed discrete accumulation of
Rhodamine structures, which were ca. 5–15 μm in size in various areas
of the brain (Fig. 3D) (shown are the dentatus gyrus of hippocampus and
(caption on next page)
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cortex). In contrast, mice treated with free Rhodamine showed a dif-
fused staining in the brain.
3.6. Effect of EGCG/AA NPs on BBB integrity
NPs have been proposed to facilitate or even open a specific trans-
port route across the BBB [58,59]. Passage of EGCG/AA NPs-Rho was
assessed using rat primary BMVECs, a well-established in vitro model of
BBB [41]. Added apically at concentrations of 15 of 15, 50, 150 and
500 μg/ml EGCG/AA NPs-Rho crossed BBB cell monolayers in con-
centration dependent manner (Fig. 4A), initially being mostly linear but
then plateauing when reaching the equilibrium concentration (kineti-
cally fitting an exponential one-phase association model).
Free EGCG at and above 15 μg/ml, EGCG/AA NPs at and above
EGCG concentration of 15 μg/ml as well as empty NPs at equivalent
concentrations induced significantly enhanced 4 kDa dextran flux in
cultured primary rat BMVECs (Fig. 4B). They also induced disruption of
BMVEC electrical barrier indicating that tight junctions were affected
(Fig. 4C). Indeed, immunohistochemical analysis showed that junc-
tional Claudin-5 was lost from primary BMVEC monolayers treated with
increasing concentrations of free EGCG, empty and EGCG/AA NPs
(Fig. 4D). Excessive leakage was also observed in rat ex vivo brains in
response to free EGCG, empty NPs and EGCG/AA NPs at and above
concentrations (or equivalents) of 150 μg/ml (Fig. 4E), indicating that
EGCG and empty NPs themselves could disrupt the BBB.
3.7. EGCG/AA NPs increase synaptic expression in APP/PS1 mice
We next investigated the therapeutic effect of EGCG/AA NPs in
APP/PS1 mice. Synaptic loss, as evidenced by decreased SYN im-
munoreactivity in the hippocampus area of patients with early and
stablished AD and demented individuals, correlates with the develop-
ment of neuropathology and severe cognitive deficit [60]. APP/PS1
mice showed reduction of SYN staining in the CA3 region of hippo-
campus. In contrast, APP/PS1 mice, treated with either free or NPs
formulated EGCG, displayed enhanced SYN staining. In fact, EGCG/AA
NPs group showed even higher SYN staining than the WT group
(Fig. 5A). 3D surface mapping analysis confirmed these results
(Fig. 5B).
3.8. EGCG/AA NPs reduce neuroinflammation and Aβ plaque/peptide
burden in APP/PS1 mice
Neuroinflammation with accompanying accumulation of Aβ pla-
ques plays a crucial role in the pathogenesis of AD [61]. Astrocyte ac-
tivation and concomitant enhanced GFAP expression have been widely
used as a neuroinflammatory indicator [62]. Neuroinflammation and
Aβ plaque accumulation was assessed in WT and APP/PS1 mice by
TheS and GFAP staining (Fig. 6A). Hippocampal and cortical areas of
APP/PS1 mice displayed much stronger GFAP reactivity as well as al-
tered morphology when compared to that of WT littermates. Treatment
of APP/PS1 mice with free EGCG had little effect on GFAP expression.
However, EGCG/AA NPs treatment strongly reduced GFAP reactivity,
with observed levels similar to those of WT littermates. APP/PS1 mice
showed Aβ plaques accumulation in these cerebral areas analysed.
Whilst treatment with either free or NP encapsulated EGCG showed
Fig. 2. Stability and in vitro drug release results. (A) Backscattering profile of
EGCG/AA NPs at 25 °C showed nanovehicle instability after 4months. (B)
Backscattering profile of EGCG/AA NPs stored at 4 °C did not show any in-
stability for up to 11months. (C) EGCG chemical stability in different solutions,
formulations and storage temperatures. EGCG showed a significant increase in
the stability after the addition of AA to the medium and its incorporation into
PEGylated PLGA NPs. (D) In vitro drug release of EGCG/AA NPs and free EGCG.
In each condition 25mg of EGCG were dialysed in a total volume of 150ml.
Thus 0.167mg/ml was 100% of the maximal equilibrium concentration.
Cumulative drug release from EGCG/AA NPs at 24 h= 48.6%. Data shown was
from triplicate experiments.
Fig. 3. In vivo biodistribution and pharmacokinetics of EGCG/AA NPs. 3months-old C57BL/6 WT mice were treated with a single oral dose of EGCG/AA NPs and
EGCG/AA NPs-Rho 40mg/kg. (A) Histograms show biodistribution of EGCG in brain, liver, stomach, intestine, kidneys, heart, lungs and pancreas of mice after 24 h
of EGCG/AA NPs administration. Data expressed as EGCG amount per mg of tissue. Mean administered volume of EGCG/AA NPs was 448 μl (1.120mg). Mean brain
EGCG concentration was 0.6 ng/ml. With mean brain weight of 470mg this represented 0.025% of administered EGCG. (B) Plasma and (C) brain pharmacokinetic
profile of EGCG following single oral dose administration of free EGCG or EGCG/AA NPs (40mg/kg). Data expressed as EGCG amount per ml of plasma and EGCG
amount per mg of tissue, respectively. (D) Rhodamine detection in the dentatus gyrus of the hippocampus and the cortex of mice treated with EGCG/AA NPs-Rho
(40mg/kg) or free Rhodamine (2.7mg/kg). Scale bar 50 μm.
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reduction of Aβ plaques in the hippocampus, the reduction was sig-
nificantly greater in the EGCG/AA NPs treated group (Fig. 6B). Cortical
Aβ plaque count revealed that both treatments were equally effective in
reducing the number of Aβ plaques (Fig. 6C).
Soluble and insoluble Aβ42 peptide was quantified in cortical ex-
tracts of APP/PS1 mice by ELISA. Oral EGCG/AA NPs treatment led to a
significant reduction of both soluble and insoluble Aβ42 peptide in the
cortex (Fig. 6D and E). However, treatment with free EGCG did not
show any significant reduction in either Aβ42 peptide population.
Taken together these data indicated that EGCG/AA NPs were more
effective in reducing neuroinflammation and pathological Aβ accumu-
lation in APP/PS1 mice.
3.9. EGCG/AA NPs improve EGCG effectiveness on spatial memory and
learning process in APP/PS1 mice
The behaviour of APP/PS1 transgenic mice was assessed following
EGCG treatment for 3 mo. Mice were subjected to a MWM test as
measure for learning ability and spatial memory mechanisms [63].
APP/PS1 mice displayed significantly longer escape latency time than
WT control mice. Following treatment with free or NPs formulated
EGCG, APP/PS1 mice showed a significant decrease in escape latency
time during the training phase (Fig. 7A). On the day of the test, EGCG/
AA NPs treated APP/PS1 mice showed a significantly reduced escape
latency time, which was similar to WT mice (Fig. 7B). Free EGCG
treatment also significantly reduced escape latency on the test day,
however it was still significantly longer than that of EGCG/AA NPs
treated APP/PS1 mice. APP/PS1 also showed significantly reduced
exploration time in the target quadrant. Exploration time was sig-
nificantly enhanced with either EGCG treatment (Fig. 7C). Additionally,
the time spent in the border area was analysed as indicator of the an-
xiety level. Results revealed that both treated groups significantly dis-
played reduced border exploration time, nearly at levels of WT controls
(Fig. 7D).
3.10. EGCG/AA NPs improve EGCG effect on cognitive process in APP/PS1
mice
The NOR test, which is based on the natural tendency of mice to
explore new objects and environments is widely used in the evaluation
of short- and long-term cognitive deficits in AD [48]. APP/PS1 mice
were treated with EGCG/AA NPs or free EGCG for 12weeks. Assess-
ment by NOR test showed a significant improvement in performance in
both treated groups. Significantly, the EGCG/AA NPs group performed
even better results than the free drug group, with similar NOR scores
than those observed in the WT group (Fig. 7E). Taken together these
data indicated that EGCG/AA NPs offered a significant treatment ad-
vantage over free EGCG.
4. Discussion
Neurodegeneration and dementia associated with AD is the result of
many cytological and biochemical alterations in the brain [1]. There
are currently no effective treatments and in this context, our study fo-
cused on developing EGCG as a new therapeutic option for AD. Spe-
cially we opted to address this drug's inherent chemical instability and
resulting low bioavailability [24] by incorporating it into polymeric
NPs. Nanovehicle incorporation stabilised EGCG, produced a better
pharmacokinetic profile of EGCG with higher concentrations in the
brain and, in APP/PS1 mice, was more effective in reducing neuroin-
flammation and Aβ accumulation and in improving cognitive deficits.
We chose to formulate EGCG in polymeric nanostructures of PLGA
based matrix. PLGA was one of the first polymers approved by US Food
and Drug Administration for biomedical applications because of its
biocompatibility, biodegradability and non-toxicity [64]. Overall, the
biocompatibility and safety of PLGA NPs has been demonstrated and
does not involve a risk of peripheral side effects [72,73]. PLGA is widely
used in nanomedicine for brain diseases, since it possesses a great
versatility in its manufacture, physicochemical properties and functio-
nalization [65]. Likewise, PEGylated polymeric matrix was used, since
it is well described that the coating with PEG enhance a rapid spread of
carried drugs within brain tissue [66]. Conjugation of PEG to the NPs
surface may also contribute to an enhanced penetration across the in-
testinal barrier, since PEGylation has been described to increase the
permeability coefficient of solid lipid nanoparticles by 1.5–2 times and
their resulting bioavailability by 1.99 to 7.5 times [67]. Additionally,
our EGCG/AA NPs were formulated with Tween®80 as surfactant (final
concentration 1.016%) since this has been reported to facilitate brain
uptake of a number of drugs [68]. Lastly, we chose to incorporate AA
together with EGCG in NPs with the aim to provide a stabilizing, anti-
oxidant environment. AA, together with EGCG, may also mitigate po-
tential local inflammatory response [69,70], which has been ascribed to
hydrolytic degradation products derived from PLGA during chronic
administration [71]. We have used similar EGCG PLGA NPs before,
albeit at lower drug and surfactant concentration and without AA, with
demonstrable therapeutic benefits in a mouse model of epilepsy [40].
Our optimized formulation of EGCG/AA NPs significantly enhanced
shelf stability of EGCG, in particular in an aqueous environment and
demonstrated adequate properties for enhanced brain delivery. With
our formulation, we achieved small Zav, monomodal population and
negative surface charge, which contributes to enhance the stability of
NPs due to the increase of repulsion forces. In fact, PLGA matrix com-
monly suffers surface erosion and is degraded through a hydrolytic
cleavage of its polyester backbone, resulting in smaller structures of
byproducts, which also contains encapsulated drug [74]. These pro-
cesses give rise to a reduction of particle size, which could also con-
tribute to the enhancement of encapsulated drug penetration.
Importantly, EGCG showed an adequate and sustained release pro-
file from the polymeric nanostructures, indicating suitability for long-
term treatment. Taken together EGCG/AA NPs showed the desired
Table 2
Pharmacokinetic parameters of an oral gavage administration of EGCG/AA NPs and free EGCG 40mg/kg in 3months-old C57BL/6 mice. Non-compartmental model.
Parameter EGCG/AA NPs Free EGCG Unit EGCG/AA NPs Free EGCG Unit
Plasm Brain
AUCa 10270.624± 123.564 4509.790 ± 65.411 h.ng/ml 14.410 ± 3.511 6.426 ± 0.811 h.ng/mg
Cmax 842.590 ± 78.911 1078.976 ± 242.238 ng/ml 0.908 ± 0.162 0.826 ± 0.206 ng/mg
Tmax 1.000 ± 0.000 1.000 ± 0.000 h 1.000 ± 0.000 1.000 ± 0.000 h
ʎ_z 0.013 ± 0.007 0.0871 ± 0.006 1/h 0.005 ± 0.003 0.058 ± 0.006 1/h
HL ʎ_z 52.360 ± 9.024 7.956 ± 0.625 h 128.144 ± 16.051 12.025 ± 1.009 h
Vz/F 1850.574 ± 75.166 2503.858 ± 100.021 ml NA NA ml
Cl/F 24.498 ± 7.212 218.1483 ± 46.854 ml/h NA NA ml/h
MRT∞ 75.415 ± 6.341 9.489 ± 0.079 h 184.687 ± 11.267 14.860 ± 2.362 h
a AUC was measured between 0 and 24 h.
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characteristics of enhanced stability, sustained release and physico-
chemical properties compatible with brain penetration.
A number of reports describe enhanced drug transport to the brain
when using non-ligand coated PLGA NP [59,65,75,76]. However, the
mechanism underlying these observation remains disputed [58]. Ex-
perimental data shows that PEG coating and the use of surfactants such
as Tween are important for NP formulated drug passage across the BBB
[66,68]. There is clear evidence that PLGA NPs with a Zav of around
100 nm can be specifically transported through BBB endothelial cells by
absorptive transcytosis [58,59,77]. However, it is unclear if such
transcytosis events, observed at relatively scarce numbers, contribute in
a quantitative manner to the measured drug concentrations in the brain
[58]. In the present study we have not investigated the transport of
intact NPs across the BBB directly. When using EGCG/AA NP-Rho we
observed concentration-dependent passage of Rhodamine across the
BBB in vitro, which appeared entirely diffusion controlled, suggesting
that flux occurred through gaps in the BBB. Similarly, Rhodamine ag-
gregates were observed in the hippocampus and the cortex when
EGCG/AA NP-Rho were administered in vivo. Since Rhodamine was
coupled covalently to the PLGA matrix, it is likely that intact NPs or
their hydrolytic degradation products crossed the BBB. Diameters of
Rhodamine clusters in the brain ranged from 5 to 15 μm, suggesting
aggregation of the NPs and/or their uptake by resident or migrating
phagocytic cells.
Significantly, we can report here that each of the constituent com-
ponents of EGCG/AA NPs affected BBB integrity in vitro and ex vivo,
suggesting that ultimately free or nanomaterial formulated EGCG pe-
netrated the BBB through destabilized junctions, which was in complete
agreement with our EGCG/AA NPs-Rho data. Whilst junction destabi-
lization in our models was only measurable at concentrations several
fold higher than what was observed in the plasma in vivo, it is likely
that lower EGCG/AA NPs constituent concentrations also affected BBB
integrity. In addition, given that the nanomaterial appeared aggregated
when detected in the brain, it is also possible that high localized con-
centrations of aggregated material led to severe localized tight junction
disruption and breach of the BBB similarly to what we observed in
cultured BMVEC. In addition, it is well stablished that AD pathology
involves a dysfunctional BBB with an enhanced permeability [78,79].
Indeed, APP/PS1 mice showed enhanced perivascular IgG accumula-
tion indicating a dysfunctional BBB (Fig. S5 of Supplementary mate-
rial). This contributes to the penetration of many molecules which
would not normally cross the BBB under healthy conditions [80].
Therefore, we propose that quantitative uptake of EGCG to the brain
occurred through a destabilized BBB.
Irrespective of the transport route, our study shed light on possibly
the most therapeutically important property of EGCG-loaded NPs: when
administered as PLGA-PEG nanomaterial, EGCG exhibited pharmaco-
kinetic profile with significantly enhanced residence time in blood
stream and brain tissue. When provided orally to mice either free or as
EGCG/AA NPs, EGCG accumulated rapidly in the blood, reaching peak
plasma concentrations of around 1 μg/ml within 1 h of administration.
Importantly, peak concentrations measured were similar in both cases,
indicating that the same absorption route from the GI tract to the blood
was used and that PLGA NPs did not specifically enhance GI uptake. GI
absorption of tea catechins, appears to involve active transport [81].
Importantly, longer term plasma concentrations were ca. 5 times higher
Fig. 4. Effect of EGCG formulations on in vitro models (A) Flux of 15, 50, 150 and 500 μg/ml of EGCG/AA NPs-Rho across primary rat BMVECs within the initial 2 h.
Data are showed as mean ± SD. At 1440min values of each data set showed statistical difference to each of the other groups (p < 0.001, ANOVA). (B) FITC-dextran
flux across primary rat BMVECs in the presence of 1.5, 5, 15, 50, 150 and 500 μg/ml EGCG, EGCG/AA NPs and equivalent amounts of empty NPs. Flux rates in the
absence of drug were normalised to 1. Data are showed as mean ± SEM. (C) Normalised TEER real time measurement of BMVCEs monolayer in response to 1.5, 5,
15, 50, 150 and 500 μg/ml EGCG, EGCG/AA NPs and equivalent amounts of empty NPs (added at 2 h). Shown are mean ± SEM. (D) Claudin-5 (green) and DNA
(blue) staining of BMVECs monolayer after exposure to 1.5, 5, 15, 50, 150 and 500 μg/ml EGCG, EGCG/AA NPs and equivalent amounts of empty NPs for 1 h. Scale
bar 10 μm. (E) Evans Blue/Albumin leakage response in ex vivo rat brains treated on the indicated side with 1.5, 5, 15, 50, 150 and 500 μg/ml EGCG, EGCG/AA NPs
or equivalent amounts of empty NPs for 1 h. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)
Fig. 5. Effect of EGCG treatments on SYN expression. 3months-old APP/PS1 mice were orally treated with EGCG/AA NPs or free EGCG 40mg/kg/day for 3months.
At 6months, animals were sacrificed by perfusion with 4% PFA and brains were cut with a cryostat. SYN immunostaining was performed on 20 μm coronal sections.
(A) SYN staining of CA3 hippocampus region. Scale bar 50 μm. (B) 3D surface mapping analysis of SYN staining. Interactive 3D surface Plot v 2.4, Image J. Zones with
synaptic labeling of the EGCG/AA NPs treated mice exhibited a tridimensional relief and color intensity higher to those of the WT group.
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in animals treated with EGCG/AA NPs, suggesting less degradation
(either chemical or in the liver). This pharmacokinetic profile was
mirrored in the brains of treated animals, where peak EGCG con-
centrations were also observed after around 1 h. Again subsequently,
concentrations fell rapidly but remained much higher in animals having
received EGCG/AA NPs as opposed to free EGCG. Importantly, relative
brain EGCG concentrations were similar to those in the plasma (see
footnote2), indicating that pharmacokinetic profile of EGCG in the brain
was a direct consequence of that in the plasma. Overall our results
strongly suggested that brain uptake of EGCG occurred through desta-
bilized BBB endothelial junctions by diffusion and was enhanced due to
greater stability and dwell time in the blood.
Previous studies have shown that different treatments with EGCG
improved the memory process in AD animals models [16]. Lee et al.
demonstrated this after an i.p. EGCG treatment of 3mg/kg/day during
3 weeks in a LPS-induced memory impairment mouse model of AD
[82]. We also found marked therapeutic effects of free EGCG in APP/
PS1 mice using MWM and NOR behavioural test. However, overall,
EGCG formulated as EGCG/AA NPs led to even better therapeutic
outcome than the free drug alone. Significantly, improvements were
found in spatial learning and memory (MWM test). Furthermore, NOR
test also showed that EGCG/AA NPs treatment of APP/PS1 mice re-
stored the recognition memory and enhanced cognitive process far
more than free EGCG, reaching scores comparable to those of the WT
group.
Improvement in brain function clearly had cytological and bio-
chemical basis. EGCG reduced neuroinflammation and neurodegen-
eration in agreement with published data [16]. However, we found
Fig. 6. Effect of EGCG treatments on neuroinflammation and Aβ plaque/peptide burden. (A) 3months-old APP/PS1 mice were orally treated with EGCG/AA NPs or
free EGCG 40mg/kg/day for 3 months. At 6months, animals were sacrificed by perfusion with 4% PFA and brains were cut with a cryostat. GFAP and ThS
immunostaining was performed on 20 μm coronal sections. Dentate gyrus of hippocampus and cortex area are shown. Scale bar 100 μm. Images of ThS staining of
100 μm coronal sections of perfused animals were used for Aβ plaques depositions count. Histograms show Aβ plaques depositions count at (B) hippocampus and (C)
cortex area. In ELISA kit, animals were sacrificed by cervical dislocation, and brain cortices were homogenized. Histograms show (D) soluble and (E) insoluble
amounts of Aβ(1–42) peptide expressed as pg/mg of total protein. ANOVA analysis of data is included in the table S2 of the supplementary material.
2 Assuming a density of 1.04 g/ml, mean brain concentration was ca. 624 ng/
ml, which was very similar to mean blood concentration (see Fig. 3B and C).
A. Cano, et al. Journal of Controlled Release 301 (2019) 62–75
72
even greater EGCG anti-neuroinflammatory activity, as well as a sig-
nificant decline in the accumulation of Aβ plaques, when EGCG was
supplied as EGCG/AA NPs. These findings were in accordance with
those obtained by Li et al., which showed that Aβ deposits were reduced
by 60% in the frontal cortex and 52% in the hippocampus after
3months of treatment of EGCG 20mg/kg/day by oral gavage in an APP
transgenic mice [83].
We also found a strong increase in SYN staining following treatment
of APP/PS1 mice with EGCG/AA NPs, indicating protection of synapses
and increase of synaptogenesis. This correlated well with the cognitive
improvement exhibited in behavioural tests. Many studies have de-
monstrated that small increases in the levels of Aβ42 peptide lead to
permanent synaptic function impairment and neuroinflammatory re-
sponses [84]. Indeed, the high level of both soluble and insoluble Aβ42
peptide in APP/PS1 mice was significantly reduced following EGCG/AA
NPs, but not free drug treatment.
5. Conclusions
In summary, the current work demonstrates the improvement of
EGCG stability and effectiveness when loaded in PEGylated PLGA NPs
within an antioxidant environment. EGCG/AA NPs were able to in-
crease drug permanence in blood stream and brain tissue, reduce the Aβ
plaques burden, Aβ42 peptide levels and neuroinflammation, and en-
hance synaptogenesis, memory and learning process. All these facts
contributed to a significant reduction of cognitive impairment in APP/
PS1 mice. Based on these findings, we propose EGCG/AA NPs as a
novel, safe and suitable therapeutic alternative for the treatment of AD.
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